Correlation Between Alnylam Pharmaceuticals and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Apellis Pharmaceuticals.

Diversification Opportunities for Alnylam Pharmaceuticals and Apellis Pharmaceuticals

-0.07

Correlation Coefficient

Alnylam Pharmaceuticals  Apellis Pharmaceuticals

Good diversification

The 3 months correlation between Alnylam and Apellis is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Apellis Pharmaceuticals

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 0.91 times more return on investment than Apellis Pharmaceuticals. However, Alnylam Pharmaceuticals is 1.1 times less risky than Apellis Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about -0.15 per unit of risk. If you would invest  24,226  in Alnylam Pharmaceuticals on December 22, 2024 and sell it today you would earn a total of  4,108  from holding Alnylam Pharmaceuticals or generate 16.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Apellis Pharmaceuticals

Alnylam Pharmaceuticals

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Alnylam Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Alnylam Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Apellis Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Alnylam Pharmaceuticals and Apellis Pharmaceuticals

The main advantage of trading using opposite Alnylam Pharmaceuticals and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind Alnylam Pharmaceuticals and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.